ORIGINAL RESEARCH article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1662512
This article is part of the Research TopicAdvancing Therapeutic Strategies for Relapsed/Refractory Acute Lymphoblastic LeukemiaView all 3 articles
Efficacy and safety of the third-generation tyrosine kinase inhibitor Olverembatinib in relapsed and persistent minimal residual disease positive Philadelphia chromosome-positive Acute Lymphoblastic Leukemia patients
Provisionally accepted
- Qilu Hospital of Shandong University, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study aimed to evaluate the efficacy of Olverembatinib in patients with relapsed and persistent minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia. Methods: We conducted a retrospective analysis of clinical characteristics in 22 patients diagnosed with Ph+ALL at Qilu Hospital of Shandong University and Yantai Yuhuangding Hospital between December 2018 and December 2024. Results: A cohort of 22 patients with Ph+ ALL was enrolled in this study. Among them, 12 (54.5%) patients had relapsed Ph+ ALL, while the remaining 10 patients exhibited persistent MRD positivity. In the relapsed subgroup, the CR rate following one treatment cycle reached 75.0% (9/12), with MRD-negative and MMR rates of 75.0% (9/12) and 50.0% (6/12), respectively. Upon completion of two treatment cycles in evaluable patients (n=8), the CR, MRD-negative, and MMR rates all rose to 87.5%, 87.5% and 87.5%, respectively. The patients with forfeited MMR on first or second-generation TKIs, of which the MMR rate was restored to 60.0% (6/10) after one cycle of Olverembatinib treatment, and a pleasant surprise was that their MMR rate soared to 90% (9/10) after two cycles of Olverembatinib treatment. 70% of them subsequently underwent successful hematopoietic stem cell transplantation. This is a provisional file, not the final typeset article Conclusion: The efficacy and tolerability of olverembatinib were confirmed in patients with relapsed, MRD-positive, Ph+ ALL, offering a novel therapeutic approach for these patients and making prolonged survival possible.
Keywords: Acute Lymphoblastic Leukemia, Philadelphia chromosome-positive, Relapsed, MRD-positive, tyrosine kinase inhibitor
Received: 09 Jul 2025; Accepted: 12 Sep 2025.
Copyright: © 2025 Jiang, Zhou, Ji, Li, Ma and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chunyan Chen, chency@sdu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.